Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Collegium Pharmaceutical (COLL)

Collegium Q4 revenue rises 13% to $205.4 million; full-year GAAP profit falls

Mixed Impact 3 of 5 earnings Written later

Collegium reported fourth-quarter and full-year 2025 results on February 26, 2026. Product revenues grew 13% in the quarter and 24% for the year, led by Jornay PM, but full-year GAAP net income fell to $62.9 million from $69.2 million. The company reaffirmed its 2026 guidance for product revenues, Jornay PM revenues and adjusted EBITDA.

Key points

  • Q4 2025 product revenues, net were $205.4 million, up 13% year-over-year; Jornay PM revenue was $45.9 million, up 57%.
  • FY 2025 GAAP net income was $62.9 million, or $1.73 per diluted share, versus $69.2 million, or $1.86 per diluted share, in FY 2024.
  • 2026 guidance reaffirmed: product revenues, net of $805 to $825 million and adjusted EBITDA of $455 to $475 million.
  • The company repurchased $25 million of shares in 2025 and ended the year with $386.7 million in cash, cash equivalents and marketable securities.

The filing

CompanyCollegium Pharmaceutical (COLL)
Form8-K, current report
Filed with the SECFeb 26, 2026, 7:32 AM ET
Accession number0001628280-26-011990

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.